Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

721. Clozapine versus typical neuroleptic medication for schizophrenia. (PubMed)

Clozapine versus typical neuroleptic medication for schizophrenia. Long-term drug treatment of schizophrenia with typical antipsychotics has limitations: 25 to 33% of patients have illnesses that are treatment-resistant. Clozapine is an antipsychotic drug, which is claimed to have superior efficacy and to cause fewer motor adverse effects than typical drugs for people with treatment-resistant illnesses. Clozapine carries a significant risk of serious blood disorders, which necessitates (...) mandatory weekly blood monitoring at least during the first months of treatment.To evaluate the effects of clozapine compared with typical antipsychotic drugs in people with schizophrenia.For the current update of this review (March 2006) we searched the Cochrane Schizophrenia Group Trials Register.All relevant randomised clinical trials (RCTs).We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis

2009 Cochrane

722. Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. (PubMed)

Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. Many people with schizophrenia experience stigma caused by other people's knowledge, attitudes, and behaviour; this can lead to impoverishment, social marginalisation, and low quality of life. We aimed to describe the nature, direction, and severity of anticipated and experienced discrimination reported by people with schizophrenia.We did a cross-sectional survey in 27 (...) countries, in centres affiliated to the INDIGO Research Network, by use of face-to-face interviews with 732 participants with schizophrenia. Discrimination was measured with the newly validated discrimination and stigma scale (DISC), which produces three subscores: positive experienced discrimination; negative experienced discrimination; and anticipated discrimination.Negative discrimination was experienced by 344 (47%) of 729 participants in making or keeping friends, by 315 (43%) of 728 from family

2009 Lancet

723. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. (PubMed)

Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Whether schizophrenia and bipolar disorder are the clinical outcomes of discrete or shared causative processes is much debated in psychiatry. We aimed to assess genetic and environmental contributions to liability for schizophrenia, bipolar disorder, and their comorbidity.We linked the multi-generation register, which contains information about all children and their parents (...) in Sweden, and the hospital discharge register, which includes all public psychiatric inpatient admissions in Sweden. We identified 9 009 202 unique individuals in more than 2 million nuclear families between 1973 and 2004. Risks for schizophrenia, bipolar disorder, and their comorbidity were assessed for biological and adoptive parents, offspring, full-siblings and half-siblings of probands with one of the diseases. We used a multivariate generalised linear mixed model for analysis of genetic

Full Text available with Trip Pro

2009 Lancet

724. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. (PubMed)

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Because of the debate about whether second-generation antipsychotic drugs are better than first-generation antipsychotic drugs, we did a meta-analysis of randomised controlled trials to compare the effects of these two types of drugs in patients with schizophrenia.We compared nine second-generation antipsychotic drugs with first-generation drugs for overall efficacy (main outcome), positive

2009 Lancet

725. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials

Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

726. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study)

UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

727. CBT for schizophrenia.

CBT for schizophrenia. September 2009 1 Evidence Briefing for Leeds Partnerships NHS Foundation Trust Cognitive behaviour therapy for schizophrenia  The NICE clinical guideline on schizophrenia 1 recommends that cognitive behaviour therapy (CBT) should be offered to all people with schizophrenia.  This recommendation is based primarily on evidence that CBT can reduce hospitalisation compared with standard care. A meta-analysis of randomised trials reported a 24% relative reduction (...) is limited but an economic model produced by the NICE Guideline Development Group indicated that provision of CBT is likely to result in cost savings overall.  The performance of Leeds Partnership Foundation Trust (LPFT) in providing CBT for service users with schizophrenia was rated ‘average’ by the Care Quality Commission in 2005/6 and 2007/8. An internal audit (April 2009) revealed that 17 out of 75 eligible service users had been offered CBT; 27 people were offered other psychosocial interventions

2009 Evidence briefings

728. Physical health monitoring for people with schizophrenia or other serious mental

Physical health monitoring for people with schizophrenia or other serious mental November 2009 1 Evidence Briefing for NHS Bradford and Airedale Physical health monitoring for people with schizophrenia or other serious mental illness ? The NICE clinical guideline on schizophrenia 1 recommends that GPs and other primary healthcare professionals should monitor the physical health of people with schizophrenia at least once a year. The assessment should focus on cardiovascular disease risk (...) assessment. ? Physical health reviews for people with schizophrenia and other serious mental illness form part of the National Quality and Outcomes Framework. ? An initial audit of 12 general practices in Bradford and Airedale revealed that while all practices had a case register of people with serious mental illness, none of the patient records examined reported a formal assessment of cardiovascular risk. Only 37% of patients had a record of cholesterol within the past 15 months. If these data

2009 Evidence briefings

729. Cognitive behaviour therapy for schizophrenia

Cognitive behaviour therapy for schizophrenia Cognitive behaviour therapy for schizophrenia Cognitive behaviour therapy for schizophrenia Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Centre for Reviews and Dissemination. Cognitive behaviour therapy for schizophrenia. University of York. Evidence (...) briefings. 2009 Authors' conclusions The NICE clinical guideline on schizophrenia1 recommends that cognitive behaviour therapy (CBT) should be offered to all people with schizophrenia. This recommendation is based primarily on evidence that CBT can reduce hospitalisation compared with standard care. A meta-analysis of randomised trials reported a 24% relative reduction in hospitalisation at follow-up (up to 18 months after treatment). Duration of hospitalisation was reduced by an average of 8 days

2009 Health Technology Assessment (HTA) Database.

730. Physical health monitoring for people with schizophrenia or other serious mental illness

Physical health monitoring for people with schizophrenia or other serious mental illness Physical health monitoring for people with schizophrenia or other serious mental illness Physical health monitoring for people with schizophrenia or other serious mental illness Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Centre for Reviews and Dissemination. Physical health monitoring for people with schizophrenia or other serious mental illness . University of York. Evidence briefings. 2009 Authors' conclusions The NICE clinical guideline on schizophrenia recommends that GPs and other primary healthcare professionals should monitor the physical health of people with schizophrenia at least once a year. The assessment should focus on cardiovascular disease risk assessment. Physical health reviews

2009 Health Technology Assessment (HTA) Database.

731. [Physical disease in schizophrenia: systematic review and analysis of hospital records]

[Physical disease in schizophrenia: systematic review and analysis of hospital records] Patologia fisica en la esquizofrenia. Revision sistematica y analisis de registros hospitalarios [Physical disease in schizophrenia: systematic review and analysis of hospital records] Patologia fisica en la esquizofrenia. Revision sistematica y analisis de registros hospitalarios [Physical disease in schizophrenia: systematic review and analysis of hospital records] Bouza Alvarez C, Lopez Cuadrado T, Saz (...) in schizophrenia: systematic review and analysis of hospital records] Madrid: Agencia de Evaluacion de Tecnologias Sanitarias (AETS). IPE 58/2009. 2009 Authors' objectives To systematically analyze the scientific evidence that supports the concept of a greater morbidity and mortality with physical causes in patients with schizophrenia versus those of the general population, combining a review of literature with an analysis of hospital records. Authors' conclusions Establish appropriate monitoring systems

2009 Health Technology Assessment (HTA) Database.

732. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials

Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled (...) trials Edwards SJ, Smith CJ CRD summary The authors concluded that antipsychotics had mixed tolerability profiles, with different treatments being better tolerated depending on the outcome assessed. The conclusions reflect the evidence presented, and despite some methodological weaknesses are likely to be reliable. Authors' objectives To compare the tolerability profiles of atypical antipsychotics in adults with schizophrenia or bipolar disorder. Searching BIOSIS Previews, Cochrane Central Register

2009 DARE.

733. Antipsychotic effects on cognition in schizophrenia: a meta-analysis of randomised controlled trials

Antipsychotic effects on cognition in schizophrenia: a meta-analysis of randomised controlled trials Antipsychotic effects on cognition in schizophrenia: a meta-analysis of randomised controlled trials Antipsychotic effects on cognition in schizophrenia: a meta-analysis of randomised controlled trials Guilera G, Pino O, Gomez-Benito J, Rojo JE CRD summary This review explored the effects of antipsychotics on cognition and showed that atypical antipsychotics produced a slight improvement (...) in the global cognitive index and in several cognitive domains, compared with typical antipsychotics. The potential for publication bias could not be excluded, due to a restricted search, and the authors' conclusions should be treated with caution. Authors' objectives To explore the effects of antipsychotics on cognition in patients with schizophrenia. Searching MEDLINE was searched in November 2008 for relevant studies. Search terms were reported and references of retrieved studies and other reviews were

2009 DARE.

734. Parental violent crime, previous violence and substance abuse predict future violence in people with schizophrenia

Parental violent crime, previous violence and substance abuse predict future violence in people with schizophrenia Parental violent crime, previous violence and substance abuse predict future violence in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Parental violent crime, previous violence and substance abuse predict future violence in people with schizophrenia Article Text Aetiology Parental violent crime

2009 Evidence-Based Mental Health

735. Review: limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia

Review: limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia Review: limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: limited evidence that adding a second antipsychotic improves clozapine treatment in schizophrenia Article Text Therapeutics Review: limited evidence that adding a second

2009 Evidence-Based Mental Health

736. Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia

Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Article Text Therapeutics Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Statistics from

2009 Evidence-Based Mental Health

737. Schizophrenia in either parent increases risk of infant mortality

Schizophrenia in either parent increases risk of infant mortality Schizophrenia in either parent increases risk of infant mortality | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Schizophrenia in either parent increases risk of infant mortality Article Text Aetiology Schizophrenia in either parent increases risk of infant mortality Statistics from Altmetric.com QUESTION Question: Is schizophrenia in either parent associated

2009 Evidence-Based Mental Health

738. Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia

Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adjunctive transdermal oestradiol improves positive symptoms and general psychopathology in women with schizophrenia Article Text Therapeutics Adjunctive

Full Text available with Trip Pro

2009 Evidence-Based Mental Health

739. Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder

Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective

2009 Evidence-Based Mental Health

740. Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms

Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms Article Text Therapeutics Refractory schizophrenia: adding aripiprazole to clozapine

2009 Evidence-Based Mental Health